Cane Capital Partners’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$441K Sell
3,035
-162
-5% -$22.4K 0.16% 92
2026
Q2
$411K Buy
3,197
+407
+15% +$47.6K 0.16% 95
2026
Q1
$336K Sell
2,790
-75
-3% -$8.66K 0.15% 88
2025
Q4
$302K Hold
2,865
– – 0.12% 112

Other funds holding MRK

Cane Capital Partners's MRK Position: Q3 2026 in Review

Cane Capital Partners reduced its Merck (MRK) stake by 5.1% in Q3 2026, selling an estimated $22.4K and leaving 3,035 shares worth $441K. The position accounts for 0.16% of the portfolio, ranked #92.

Cane Capital Partners first reported a position in MRK in Q4 2025 and has held it in 4 quarters since. 3,977 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • Cane Capital Partners held 3,035 shares of Merck worth $441K as of Q3 2026.
  • Cane Capital Partners sold 162 Merck shares in Q3 2026, an estimated $22.4K.
  • Merck made up 0.16% of Cane Capital Partners's portfolio in Q3 2026, its #92 holding.
  • Cane Capital Partners first reported a position in Merck in Q4 2025 and has held it in 4 quarters since.
  • 3,977 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on Cane Capital Partners's 13F filing for Q3 2026, filed 23 Oct 2026.